News

The COPD therapy-development partners Theravance Biopharma and Mylan have submitted a New Drug Application for revefenacin (TD-4208) to the U.S. Food and Drug Administration. Revefenacin is a long-lasting mist. The partners designed it so that chronic obstructive pulmonary disease need to take it only once a day. The therapy is called…

Boehringer Ingelheim will host a live event on Facebook and Twitter on Nov. 15 — World COPD Day — to increase awareness about how people with chronic obstructive pulmonary disease (COPD) can improve their quality of life. This year’s World COPD Day is led by the Global Initiative for…

Verona Pharma has enrolled more than half of the 400 COPD patients it is seeking for a Phase 2b clinical trial of its therapy candidate RPL554, putting the program ahead of schedule. This means the company may be able to report the results of the study by mid-2018, sooner than expected. The…

GlaxoSmithKline (GSK) and Innoviva recently presented positive results of a study showing that Anoro Ellipta is more effective than Stiolto Respimat in symptomatic patients with chronic obstructive pulmonary disease (COPD). The results were presented at the 2017 CHEST Annual Meeting of the American College of Chest Physicians in Toronto, Canada,…

Pooled data from three Phase 3 clinical trials shows that the investigative SUN-101/eFlow product is well-tolerated and improves lung function in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD). Data from the GOLDEN-3, GOLDEN-4, and GOLDEN-5 clinical studies were subject of poster presentations during the American College of…

People with chronic obstructive pulmonary disease (COPD) will soon have new resources available to them following the partnership of the COPD Foundation, Jvion, Geisinger, and GSK to find new ways to promote patient health, avoid hospitalizations, and prevent readmissions after an inpatient stay. The venture will…

Seebri Neohaler, a long-term maintenance therapy for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), is now available at U.S. pharmacies. “COPD is a serious, progressive respiratory disease that should have a personalized approach to choosing a therapy and delivery method,” Dr. Edward Kerwin, medical director of the…

E-cigarettes are not at all beneficial for chronic obstructive pulmonary disease (COPD) patients trying to quit smoking or to mitigate the health consequences of nicotine, according to a new study. The study reporting the findings was published in the Journal of General Internal Medicine and is titled “…

Researchers from the Imperial College London in England and the National University of Singapore (NUS) have identified a grape polyphenol, known as isorhapontigenin, which shows potential for suppressing lung inflammation caused by chronic obstructive pulmonary disease (COPD). The naturally-derived compound belongs to the family of polyphenols, which are found abundantly…

The AIRWISE phase 4 clinical trial aiming to assess how commonly prescribed medicines may decrease the worsening of symptoms in chronic obstructive pulmonary disease (COPD) has begun enrolling the first patients. The AIRWISE trial (NCT03265145) is described as the world’s largest ever pragmatic clinical trial,…